Gilead, Arcus hope to ease TIGIT anxieties with latest trial data tease

The jury remains out on the prospects of anti-TIGIT checkpoint inhibitors but Gilead and Arcus Biosciences are hoping to ease concerns that the modality is a bust, teasing new phase 2 data.